GB0614755D0 - Cytokine derivatives - Google Patents

Cytokine derivatives

Info

Publication number
GB0614755D0
GB0614755D0 GBGB0614755.7A GB0614755A GB0614755D0 GB 0614755 D0 GB0614755 D0 GB 0614755D0 GB 0614755 A GB0614755 A GB 0614755A GB 0614755 D0 GB0614755 D0 GB 0614755D0
Authority
GB
United Kingdom
Prior art keywords
terminal portion
cytokine derivatives
cytokine
derivatives
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0614755.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Geneva filed Critical University of Geneva
Priority to GBGB0614755.7A priority Critical patent/GB0614755D0/en
Publication of GB0614755D0 publication Critical patent/GB0614755D0/en
Priority to MEP-2011-47A priority patent/ME01320B/me
Priority to DK07825334.1T priority patent/DK2076532T3/da
Priority to JP2009521377A priority patent/JP5224603B2/ja
Priority to HR20110146T priority patent/HRP20110146T1/hr
Priority to MX2009000918A priority patent/MX2009000918A/es
Priority to RS20110103A priority patent/RS51854B/sr
Priority to HK09109545.2A priority patent/HK1131162B/en
Priority to RU2009106436/10A priority patent/RU2461567C2/ru
Priority to SI200730500T priority patent/SI2076532T1/sl
Priority to AU2007278894A priority patent/AU2007278894B2/en
Priority to PCT/IB2007/003026 priority patent/WO2008012689A2/en
Priority to AT07825334T priority patent/ATE490270T1/de
Priority to DE602007010969T priority patent/DE602007010969D1/de
Priority to KR1020097003947A priority patent/KR101530353B1/ko
Priority to ES07825334T priority patent/ES2361455T3/es
Priority to PL07825334T priority patent/PL2076532T3/pl
Priority to PT07825334T priority patent/PT2076532E/pt
Priority to US12/309,569 priority patent/US8686111B2/en
Priority to BRPI0715331A priority patent/BRPI0715331B8/pt
Priority to CA2658806A priority patent/CA2658806C/en
Priority to NZ575092A priority patent/NZ575092A/en
Priority to CN200780032719.1A priority patent/CN101511867B/zh
Priority to EP07825334A priority patent/EP2076532B1/en
Priority to ZA2009/01342A priority patent/ZA200901342B/en
Priority to CY20111100216T priority patent/CY1111630T1/el
Priority to US13/909,845 priority patent/US9328153B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
GBGB0614755.7A 2006-07-25 2006-07-25 Cytokine derivatives Ceased GB0614755D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
EP07825334A EP2076532B1 (en) 2006-07-25 2007-07-25 Cytokine derivatives
AT07825334T ATE490270T1 (de) 2006-07-25 2007-07-25 Zytokinderivate
KR1020097003947A KR101530353B1 (ko) 2006-07-25 2007-07-25 사이토킨 유도체
JP2009521377A JP5224603B2 (ja) 2006-07-25 2007-07-25 サイトカイン誘導体
HR20110146T HRP20110146T1 (hr) 2006-07-25 2007-07-25 Derivati citokina
MX2009000918A MX2009000918A (es) 2006-07-25 2007-07-25 Derivados de citocina.
RS20110103A RS51854B (sr) 2006-07-25 2007-07-25 Derivati citokina
HK09109545.2A HK1131162B (en) 2006-07-25 2007-07-25 Cytokine derivatives
RU2009106436/10A RU2461567C2 (ru) 2006-07-25 2007-07-25 Полипептид, способный блокировать рецептор клеточной поверхности ccr5 и/или вызывать интернализацию и/или подавляющую регуляцию ccr5 в клетке-мишени, кодирующая его нуклеиновая кислота, клетка-хозяин, применение (варианты), фармацевтическая композиция и способ лечения или профилактики вич-инфекции у пациента (варианты)
SI200730500T SI2076532T1 (sl) 2006-07-25 2007-07-25 Derivati citokina
AU2007278894A AU2007278894B2 (en) 2006-07-25 2007-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives
MEP-2011-47A ME01320B (me) 2006-07-25 2007-07-25 Derivati citokina
DE602007010969T DE602007010969D1 (de) 2006-07-25 2007-07-25 Zytokinderivate
DK07825334.1T DK2076532T3 (da) 2006-07-25 2007-07-25 Cytokinderivater
ES07825334T ES2361455T3 (es) 2006-07-25 2007-07-25 Derivados de citocinas.
PL07825334T PL2076532T3 (pl) 2006-07-25 2007-07-25 Pochodne cytokin
PT07825334T PT2076532E (pt) 2006-07-25 2007-07-25 Derivados de citocina
US12/309,569 US8686111B2 (en) 2006-07-25 2007-07-25 Cytokine derivatives
BRPI0715331A BRPI0715331B8 (pt) 2006-07-25 2007-07-25 polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
CA2658806A CA2658806C (en) 2006-07-25 2007-07-25 Cytokine derivatives
NZ575092A NZ575092A (en) 2006-07-25 2007-07-25 N-terminally modified RANTES (CCL5) chemokines comprisng the consensus sequence QGP[P or L]
CN200780032719.1A CN101511867B (zh) 2006-07-25 2007-07-25 细胞因子衍生物
ZA2009/01342A ZA200901342B (en) 2006-07-25 2009-02-24 Cytokine derivatives
CY20111100216T CY1111630T1 (el) 2006-07-25 2011-02-23 Παραγωγα κυτοκινων
US13/909,845 US9328153B2 (en) 2006-07-25 2013-06-04 Cytokine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
GB0614755D0 true GB0614755D0 (en) 2006-09-06

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0614755.7A Ceased GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
AU2019276939A1 (en) 2018-05-28 2021-01-21 Orion Biotechnology Switzerland Sàrl CCR5 inhibitor for use in treating cancer
EP3813869B1 (en) * 2018-05-28 2023-10-18 Université de Genève Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
ME01320B (me) 2013-12-20
US9328153B2 (en) 2016-05-03
BRPI0715331B8 (pt) 2021-05-25
WO2008012689A3 (en) 2008-05-08
SI2076532T1 (sl) 2011-06-30
EP2076532B1 (en) 2010-12-01
CA2658806C (en) 2017-01-03
ES2361455T3 (es) 2011-06-17
JP2009544304A (ja) 2009-12-17
CN101511867B (zh) 2014-04-09
RS51854B (sr) 2012-02-29
HK1131162A1 (en) 2010-01-15
PL2076532T3 (pl) 2011-07-29
KR20090060281A (ko) 2009-06-11
HRP20110146T1 (hr) 2011-06-30
NZ575092A (en) 2011-08-26
JP5224603B2 (ja) 2013-07-03
US20130330305A1 (en) 2013-12-12
WO2008012689A2 (en) 2008-01-31
US20090317363A1 (en) 2009-12-24
RU2009106436A (ru) 2010-08-27
CN101511867A (zh) 2009-08-19
DK2076532T3 (da) 2011-03-07
CA2658806A1 (en) 2008-01-31
ZA200901342B (en) 2010-11-24
KR101530353B1 (ko) 2015-06-26
BRPI0715331B1 (pt) 2021-04-13
ATE490270T1 (de) 2010-12-15
MX2009000918A (es) 2009-08-26
CY1111630T1 (el) 2015-10-07
AU2007278894B2 (en) 2012-08-09
US8686111B2 (en) 2014-04-01
PT2076532E (pt) 2011-03-02
DE602007010969D1 (de) 2011-01-13
RU2461567C2 (ru) 2012-09-20
AU2007278894A1 (en) 2008-01-31
EP2076532A2 (en) 2009-07-08
BRPI0715331A2 (pt) 2013-07-16

Similar Documents

Publication Publication Date Title
NZ600731A (en) Oxyntomodulin peptide analogue
NZ600732A (en) Oxyntomodulin peptide analogue
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ600690A (en) Fkbp-l and uses thereof
IN2014CN02050A (enExample)
UA103215C2 (uk) Поліпептид з ксиланазною активністю
ZA200901342B (en) Cytokine derivatives
WO2008038287A3 (en) N-terminal fgf variants having increased receptor selectivity and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2005068494A3 (en) Chimera botulinum toxin type e
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
NZ609216A (en) Anticancer fusion protein
EP2455461A3 (en) Lipase variants for pharmaceutical use
NZ707439A (en) Modified factor ix polypeptides and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
WO2008113536A8 (en) Neurotrophic peptides
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
WO2010057242A3 (de) Vakzin
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)